Medicine
Ziihera 50 mg/mL powder for injection
Ziihera 50 mg/mL powder for injection is a prescription medicine containing Zanidatamab for intravenous use, marketed by Jazz Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton…
Key facts
- Active ingredient (INN)
- Zanidatamab
- Brand
- Ziihera
- Strength
- 50 mg/mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 2 vials
- Marketing authorisation holder
- Jazz Pharmaceuticals
- Manufacturer
- Jazz Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton until time of reconstitution.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FD07 Zanidatamab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 November 2024
- Identifiers
- RxCUI 2698206, 2698212DailyMed set ID ae5d9425-fae5-4541-a158-150998343348NDC 68727-950Application BLA761416
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 vial, single-dose in 1 carton / 6 mL in 1 vial, single-dose | 68727-950-02 | Jazz Pharmaceuticals | 20 November 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Zanidatamab is a bispecific HER2-directed antibody indicated for gastroesophageal Adenocarcinoma (GEA), among other approved uses. It is available as powder for injection for intravenous use. MedsAcross supplies Zanidatamab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ZanidatamabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ZIIHERA prescribing information (Jazz Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Ziihera: European public assessment report (EPAR) · European Medicines Agency
Need Ziihera 50 mg/mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.